# Cardiff Oncology (CRDF) — Analyst Forecast

CRDF · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crdf/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 2 | 4 | 0 | 6 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 15, 2026 | HC Wainwright & Co. | Upgraded | Neutral → Buy | $9.00 |
| Aug 12, 2026 | William Blair | Downgraded | Outperform → Market Perform | — |
| Jun 3, 2026 | Craig-Hallum | Downgraded | Buy → Hold | $2.00 |
| Jun 1, 2026 | HC Wainwright & Co. | Downgraded | Buy → Neutral | — |
| Jun 1, 2026 | TD Cowen | Downgraded | Buy → Hold | — |
| Feb 25, 2026 | Piper Sandler | Maintained | Overweight | $6.00 |
| Jan 28, 2026 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Jul 8, 2025 | Ladenburg Thalmann | Initiated Coverage | Buy | $19.00 |
| Jun 24, 2025 | Jefferies | Initiated Coverage | Hold | $3.50 |
| May 9, 2025 | HC Wainwright & Co. | Maintained | Buy | $18.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Maintained | Buy | $17.00 |
| Dec 13, 2024 | Piper Sandler | Maintained | Overweight | $10.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Maintained | Buy | $13.00 |
| Sep 6, 2024 | Craig-Hallum | Initiated Coverage | Buy | $8.00 |
| May 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $14.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $14.00 |
| Mar 1, 2024 | Piper Sandler | Maintained | Overweight | $7.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Maintained | Buy | $12.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Maintained | Buy | $13.00 |

## Frequently Asked Questions

### Is CRDF a buy, sell, or hold?

Analysts covering Cardiff Oncology currently average a Hold rating: 2 buy, 4 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on CRDF?

On Sep 15, 2026, HC Wainwright & Co. upgraded Cardiff Oncology to Buy with a price target of $9.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).